Varicella-zoster virus (VZV) is responsible for two distinct clinical entities: primary chickenpox (varicella) and localized reactivation as shingles (herpes zoster). Following initial exposure, VZV establishes lifelong latency within sensory nerve ganglia. Decades later, waning cell-mediated immunity allows viral reactivation. Understanding the distinct clinical features of both phases is essential for appropriate infection control, timely post-exposure prophylaxis, and targeted immunization strategies.
Clinical Practice Concept
Routine pediatric varicella vaccination and adult recombinant immunization with Shingrix significantly reduce primary disease, painful reactivation, and severe complications like postherpetic neuralgia (PHN).
1. Clinical Spectrum & Disease Comparison
| Clinical Feature | Chickenpox (Primary Infection) | Shingles (VZV Reactivation) |
|---|---|---|
| Pathophysiology | Initial exogenous VZV exposure leading to systemic viremic dissemination. | Reactivation of latent VZV residing in cranial or dorsal root ganglia. |
| Transmission | Respiratory droplets & direct vesicular fluid contact. Highly contagious. | Direct contact with active blister fluid only (transmits VZV as primary chickenpox to non-immune contacts). |
| Clinical Presentation | Generalized pruritic rash (300–500 lesions in various stages), fever, fatigue, malaise. | Unilateral, dermatomal painful vesicular rash preceded by prodromal burning or dysesthesia. |
| Primary Complications | Secondary bacterial skin infections, VZV pneumonia, sepsis, acute cerebellar ataxia, encephalitis. | Postherpetic neuralgia (PHN), herpes zoster ophthalmicus (vision loss), Ramsay Hunt syndrome, stroke. |
2. High-Risk Populations & Post-Exposure Interventions
While varicella is often self-limiting in healthy children, specific vulnerable cohorts face heightened morbidity and mortality:
- Highest Mortality Risk: Adults aged 30–49 years, pregnant individuals, and infants.
- Healthcare Worker Immunity Requirements: While U.S. adults born before 1980 are generally presumed immune due to historical viral circulation, healthcare personnel require documented laboratory proof of immunity (positive VZV IgG titers) or complete 2-dose vaccination regardless of birth year.
| Post-Exposure Window | Prophylactic Measure & Clinical Efficacy |
|---|---|
| Within 3 Days | Varicella vaccine administration (>90% effective at preventing clinical disease). |
| Within 5 Days | Varicella vaccine administration (~70% effective at preventing disease; highly protective against severe illness). |
| High Risk / Live Vaccine Contraindicated | Varicella-Zoster Immune Globulin (VZIG) indicated for exposed non-immune individuals unable to receive live vaccines (e.g., pregnant patients, severely immunocompromised individuals). |
3. Vaccine Formulations & Dosing Schedules
| Vaccine | Type | Target Population | Dosing & Administration Schedule |
|---|---|---|---|
| Varicella Vaccine | Live Attenuated | Routine pediatric care; non-immune adults |
• Pediatric: Dose 1 at 12–15 mos; Dose 2 at 4–6 yrs. • Adult/Catch-up: 2 doses administered 4–8 weeks apart. |
| Shingrix (Preferred) | Recombinant (Non-Live) | Adults ≥50 yrs; prior Zostavax or shingles recipients |
• 2-dose intramuscular series given 2–6 months apart. • Post-shingles infection: Delay administration until acute rash resolves (~8 weeks). |
| Zostavax (Legacy) | Live Attenuated | Adults ≥60 yrs (Rarely used, lower efficacy) |
• Single dose. • Re-vaccination with 2 doses of Shingrix is strongly recommended. |
4. Live Attenuated Vaccines: Safety Considerations
Live attenuated vaccines stimulate robust humoro-cellular immunity but are contraindicated in specific patient populations:
Common Live Attenuated Vaccines
Varicella, MMR (Measles, Mumps, Rubella), Intranasal Influenza (FluMist), Zostavax, and Rotavirus.
Key Contraindications & Precautions
- Pregnancy Contraindications: Live vaccines are strictly contraindicated during pregnancy due to theoretical risks of fetal infection. Non-immune women should receive Dose 1 of the varicella vaccine postpartum prior to discharge, and Dose 2 at 4–8 weeks.
- Immunosuppression Contraindications: Live vaccines are contraindicated in patients with severe immune compromise (e.g., active chemotherapy, high-dose systemic corticosteroids, advanced untreated HIV).
- Rotavirus Exception: The rotavirus vaccine is strictly contraindicated in infants diagnosed with Severe Combined Immunodeficiency (SCID) or a history of intussusception.
Clinical Practice Pearls
- Distinguish Transmission Risk: Shingles lesions cannot cause shingles in contacts; they transmit primary varicella to VZV-naive individuals through direct fluid contact.
- Prefer Non-Live Shingrix: Recombinant Shingrix provides superior, long-lasting protection against herpes zoster and postherpetic neuralgia without the safety limitations of live vaccines in immunocompromised adults.
- Prompt PEP timing: Post-exposure varicella vaccination is most effective when administered within 72 hours of exposure.
